Atossa Therapeutics, Inc. (ATOS) stock
Close on Nov 12, 2026Market cap $19.36MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $19.36M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.89
- Dividend yield
- –
- Free cash flow yield
- -182.29%
Fundamentals
- Net income
- -$34.66M
- EPS, diluted
- -$3.89
- Free cash flow
- -$35.29M
- Book value per share
- $2.18
- Diluted shares
- 10M
Trading
- Next earnings
- Jan 8, 2027 (estimated, before the open)
- Previous close
- $2.03
- Open
- $2.03
- Day's range
- $1.81 – $2.06
- Volume
- 91,513
- Average volume (20 days)
- 63,523
- Beta (5 years)
- 1.65
- 52-week range
- $1.70 – $14.85
- RSI (14 days)
- 36.4
- Volatility (1 year)
- 91.5%
- Relative volume
- 1.29×
- WACC
- 13.1%
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ATOS | S&P 500 | Difference | ATOS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.8% | -2.7% | −16.1 pts | ||
| 3 months | -17.4% | -1.7% | −15.7 pts | ||
| Year to date | -78.1% | +11.9% | −90.0 pts | ||
| 1 year | -84.1% | +12.0% | −96.1 pts | ||
| 3 years | -79.8% | +78.2% | −158.0 pts | -41.3% | +21.2% |
| 5 years | -95.1% | +73.2% | −168.4 pts | -45.3% | +11.6% |
| 10 years | -99.4% | +309.6% | −409.0 pts | -39.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Atossa Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Update
- Results
- Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 OutlookUpdate
About Atossa Therapeutics
Pharmaceutical Preparations
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for areas of significant unmet medical need in oncology, primarily breast cancer and other breast conditions. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen designed to directly inhibit estrogen receptor signaling, induce estrogen receptor degradation, and promote apoptosis in estrogen receptor-positive breast cancer cells. In addition to breast cancer prevention and treatment across neoadjuvant and adjuvant settings, the company explores the molecule for potential rare disease indications, including Duchenne muscular dystrophy, symptomatic female carriers of the condition, and McCune-Albright syndrome.
Company profile, executives and historyAtossa Therapeutics stock: common questions
What is Atossa Therapeutics's stock price?
ATOS closed at $1.94 on Nov 12, 2026, down 4.43% on the day. Over the past 52 weeks it traded between $1.70 and $14.85.
What is Atossa Therapeutics's market cap?
Atossa Therapeutics was worth $19.36M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ATOS's P/E ratio?
Atossa Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.89), so it has no meaningful P/E ratio.
Does Atossa Therapeutics pay a dividend?
No. Atossa Therapeutics has not paid a cash dividend over the last twelve months.
When does Atossa Therapeutics report earnings next?
Atossa Therapeutics is expected to report Q4 FY2026 results on Jan 8, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ATOS stock performed over the past year?
Including dividends, ATOS returned -84.1% over the past year, against +12.0% for the S&P 500.
How many ATOS shares are sold short?
1M shares were sold short at the latest FINRA report, 5.40% of the float, or 7.6 days of average trading volume.
Who are Atossa Therapeutics's competitors?
Companies most similar to Atossa Therapeutics by business, industry and size include OLMA, PRLD, APRE, PBYI, ZNTL.
See a number that looks wrong?